Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: Implication in disease progression

Leukemia

Volumn 31, Issue 2, 2017, Pages 350-360

  Boysen, J ^a   Nelson, M ^a   Magzoub, G ^b   Maiti, G P ^b   Sinha, S ^a   Goswami, M ^a   Vesely, S K ^b   Shanafelt, T D ^a   Kay, N E ^a   Ghosh, A K ^b,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD52 ANTIGEN; IBRUTINIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE MICROPARTICLE; MEMBRANE MICROPARTICLE; PHENOTYPE; PRIORITY JOURNAL; TIME TO TREATMENT; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BIOMARKERS; CELL LINE, TUMOR; CELL-DERIVED MICROPARTICLES; DISEASE PROGRESSION; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84990886723     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.217     Document Type: Article

References (41)

1. Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'. Sem Immunopathol 2011; 33: 455-467.
2. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36: 888-906.
3. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010; 115: 1755-1764.
4. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788-794.
5. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005; 19: 513-523.
6. Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M et al. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood 2014; 124: 3101-3109.
7. Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, Stamatopoulos K et al. The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010; 115: 71-77.
8. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209: 2183-2198.
9. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313-4320.
10. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 2007; 7: 633-643.
11. Yeh YY, Ozer HG, Lehman AM, Maddocks K, Yu L, Johnson AJ et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 2015; 125: 3297-3305.
12. Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ et al. Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors. Clin Cancer Res 2015; 21: 2115-2126.
13. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011; 117: 1928-1937.
14. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-2396.
15. Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss D et al. Targeted inhibition of Axl primes chronic lymphocytic leukemia B-cells for apoptosis: synergistic/additive effects in combination with bruton tyrosine kinase inhibitors. Blood 2014; 124: 1946.
16. Shanafelt TD, LaPlant BR, Call TG, Nikcevich D, Leis JF, Ding W et al. Randomized phase II trial of pentostatin, cyclophosphamide, and rituximab with or without concurrent avastin for previously untreated B-chronic lymphocytic leukemia (CLL). Blood 2014; 124: 4673.
17. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
18. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764.
19. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-2688.
20. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001; 98: 3050-3057.
21. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846-855.
22. Zupo S, Cutrona G, Mangiola M, Ferrarini M. Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood 2002; 99: 2277-2278.
23. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ et al. Highlevel expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 3050-3058.
24. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110: 2569-2577.
25. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487-1495.
26. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
27. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118-127.
28. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089-1096.
29. Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000; 12: 505-516.
30. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004; 101: 999-1008.
31. Hale G, Waldmann H. From laboratory to clinic: the story of CAM PA TH-1. Methods Mol Med 2000; 40: 243-266.
32. Bandala-Sanchez E, Zhang Y, Reinwald S, Dromey JA, Lee BH, Qian J et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol 2013; 14: 741-748.
33. Fujimoto M, Poe JC, Inaoki M, Tedder TF. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol. 1998; 10: 267-277.
34. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 2012; 189: 2318-2325.
35. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 572-577.
36. Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC. CD19 function in central and peripheral B-cell development. Immunol Res 2005; 31: 119-131.
37. Ishiura N, Nakashima H, Watanabe R, Kuwano Y, Adachi T, Takahashi Y et al. Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation. Eur J Immunol 2010; 40: 1192-1204.
38. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000; 13: 47-57.
39. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012; 122: 2257-2266.
40. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354: 1901-1912.
41. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107-118.